Switch theme
Sign up to access all valuation multiples
Klaria Pharma Holding AB is engaged in the development and commercialization of pharmaceutical products in Sweden for migraine and cancer-related pain. Its operations are based on a patented drug delivery platform in the form of an alginate-based polymer film. Majority of the group’s operations are conducted in Sweden.
2014
6
LTM Revenue $1.5M
LTM EBITDA -$0.5M
$8.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Klaria Pharma Holding has a last 12-month revenue (LTM) of $1.5M and a last 12-month EBITDA of -$0.5M.
In the most recent fiscal year, Klaria Pharma Holding achieved revenue of $0.2M and an EBITDA of -$2.1M.
Klaria Pharma Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Klaria Pharma Holding valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | $1.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$0.5M | XXX | -$2.1M | XXX | XXX | XXX |
| EBITDA Margin | -32% | XXX | -895% | XXX | XXX | XXX |
| EBIT | -$0.5M | XXX | -$3.2M | XXX | XXX | XXX |
| EBIT Margin | -32% | XXX | -1392% | XXX | XXX | XXX |
| Net Profit | -$0.7M | XXX | -$4.9M | XXX | XXX | XXX |
| Net Margin | -51% | XXX | -2124% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Klaria Pharma Holding's stock price is SEK 0 (or $0).
Klaria Pharma Holding has current market cap of SEK 61.5M (or $6.3M), and EV of SEK 84.0M (or $8.7M).
See Klaria Pharma Holding trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.7M | $6.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Klaria Pharma Holding has market cap of $6.3M and EV of $8.7M.
Klaria Pharma Holding's trades at 37.4x EV/Revenue multiple, and -4.2x EV/EBITDA.
Equity research analysts estimate Klaria Pharma Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Klaria Pharma Holding has a P/E ratio of -8.7x.
See valuation multiples for Klaria Pharma Holding and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.3M | XXX | $6.3M | XXX | XXX | XXX |
| EV (current) | $8.7M | XXX | $8.7M | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 37.4x | XXX | XXX | XXX |
| EV/EBITDA | -18.6x | XXX | -4.2x | XXX | XXX | XXX |
| EV/EBIT | -18.6x | XXX | -2.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.7x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | -1179.1x | XXX | -7.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKlaria Pharma Holding's last 12 month revenue growth is 112%
Klaria Pharma Holding's revenue per employee in the last FY averaged $39K, while opex per employee averaged $0.6M for the same period.
Klaria Pharma Holding's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Klaria Pharma Holding's rule of X is 249% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Klaria Pharma Holding and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 112% | XXX | 227% | XXX | XXX | XXX |
| EBITDA Margin | -32% | XXX | -895% | XXX | XXX | XXX |
| EBITDA Growth | -289% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -783% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 249% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $39K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 983% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1492% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Klaria Pharma Holding acquired XXX companies to date.
Last acquisition by Klaria Pharma Holding was XXXXXXXX, XXXXX XXXXX XXXXXX . Klaria Pharma Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Klaria Pharma Holding founded? | Klaria Pharma Holding was founded in 2014. |
| Where is Klaria Pharma Holding headquartered? | Klaria Pharma Holding is headquartered in Sweden. |
| How many employees does Klaria Pharma Holding have? | As of today, Klaria Pharma Holding has 6 employees. |
| Is Klaria Pharma Holding publicy listed? | Yes, Klaria Pharma Holding is a public company listed on STO. |
| What is the stock symbol of Klaria Pharma Holding? | Klaria Pharma Holding trades under KLAR ticker. |
| When did Klaria Pharma Holding go public? | Klaria Pharma Holding went public in 2015. |
| Who are competitors of Klaria Pharma Holding? | Similar companies to Klaria Pharma Holding include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Klaria Pharma Holding? | Klaria Pharma Holding's current market cap is $6.3M |
| What is the current revenue of Klaria Pharma Holding? | Klaria Pharma Holding's last 12 months revenue is $1.5M. |
| What is the current revenue growth of Klaria Pharma Holding? | Klaria Pharma Holding revenue growth (NTM/LTM) is 112%. |
| What is the current EV/Revenue multiple of Klaria Pharma Holding? | Current revenue multiple of Klaria Pharma Holding is 6.0x. |
| Is Klaria Pharma Holding profitable? | Yes, Klaria Pharma Holding is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Klaria Pharma Holding? | Klaria Pharma Holding's last 12 months EBITDA is -$0.5M. |
| What is Klaria Pharma Holding's EBITDA margin? | Klaria Pharma Holding's last 12 months EBITDA margin is -32%. |
| What is the current EV/EBITDA multiple of Klaria Pharma Holding? | Current EBITDA multiple of Klaria Pharma Holding is -18.6x. |
| What is the current FCF of Klaria Pharma Holding? | Klaria Pharma Holding's last 12 months FCF is -$7K. |
| What is Klaria Pharma Holding's FCF margin? | Klaria Pharma Holding's last 12 months FCF margin is -1%. |
| What is the current EV/FCF multiple of Klaria Pharma Holding? | Current FCF multiple of Klaria Pharma Holding is -1179.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
